Please login to the form below

Not currently logged in
Email:
Password:

Peter Chambre joins cancer vaccine biotech Immatics

He replaces Thomas Widmann as chair of the board

Immatics Peter ChambreImmatics Biotechnologies has appointed Peter Chambré as chairman of the board to replace Thomas Widmann, who steps down after eight years in the post.

Chambré holds several chairman positions in the life sciences industry and previously served as CEO of Cambridge Antibody Technology from 2002 until its acquisition by AstraZeneca in 2006.

Paul Higham, CEO of Immatics, said: “I am delighted to welcome Peter as our new chairman. We are approaching a crucial period at Immatics, and Peter's experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximise returns to our investors.”

Chambré joins Tuebingen-based Immatics following the German biotech's recent completion of phase III patient enrollment for a trial of its therapeutic vaccine for renal cancer IMA901.

He said: “Immatics' vaccines, based on the company's highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials.

“With IMA901, Immatics' lead multi-peptide based vaccine now in phase III development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company.”

14th November 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics